AUG 7·SEC EDGARLow
Habiger David C purchased $100K of BSX
Habiger David C purchased 2,100 shares of BOSTON SCIENTIFIC CORP (BSX) at $47.59 on 2026-08-05.
StockNYSE · US · USDHealthcare · Medical Devices
$BSX
BOSTON SCIENTIFIC CORP
Price · $BSXvia TradingView
AI sentiment · 7d5 articles
- Bullish
- 0
- Neutral
- 2
- Bearish
- 3
Top stories · $BSXMore →
AUG 5·SEC EDGAR
Habiger David C purchased $57K of BSX
Habiger David C purchased 1,182 shares of BOSTON SCIENTIFIC CORP (BSX) at an average of $48.13 ($48.07–$48.59) across 2 trades over 2026-08-03 to 2026-08-04.
AUG 5·SEC EDGAR
Mahoney Michael F purchased $9.0M of BSX
Mahoney Michael F (Chairman, President & CEO) purchased 186,240 shares of BOSTON SCIENTIFIC CORP (BSX) at $48.33 ($9.00M total) on 2026-08-03.
BSX sentiment & insider activity
Over the past 7 days, alphai's AI scored 5 news stories mentioning BSX (BOSTON SCIENTIFIC CORP). Coverage has skewed bearish: 0 bullish, 2 neutral, and 3 bearish.
Recent BSX coverage spans insider activity, earnings and market movers.
In the last 30 days, BSX insiders filed 5 SEC Form 4 transactions — 5 purchases ($9.4M) and no sales. The most active reporter was Habiger David C with 3 filings.
What's driving BSX
A director open-market purchase is a modest, sentiment-oriented signal but typically does not change fundamentals or near-term valuation by itself.
This is a routine insider buy with modest size and no stated catalyst beyond the disclosed transaction.
Insider open-market buying by the CEO is a modest positive sentiment signal, but it is not a fundamental catalyst by itself.
Guidance reset and margin outlook compression increase near-term earnings risk and reduce visibility into 2027, favoring a wait-for-stabilization stance.
Guidance reset is the key tradable takeaway, with downside risk to near-term growth from WATCHMAN declines and Electrophysiology competitive pressure.
alphai scores every news story that mentions BSX with an AI model for sentiment and relevance, and aggregates insider trades from BOSTON SCIENTIFIC CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $BSX
Score
Habiger David C purchased $100K of BSX
Habiger David C purchased 2,100 shares of BOSTON SCIENTIFIC CORP (BSX) at $47.59 on 2026-08-05.
2 min readHabiger David C purchased $57K of BSX
Habiger David C purchased 1,182 shares of BOSTON SCIENTIFIC CORP (BSX) at an average of $48.13 ($48.07–$48.59) across 2 trades over 2026-08-03 to 2026-08-04.
1 min readMahoney Michael F purchased $9.0M of BSX
Mahoney Michael F (Chairman, President & CEO) purchased 186,240 shares of BOSTON SCIENTIFIC CORP (BSX) at $48.33 ($9.00M total) on 2026-08-03.
2 min readShould Investors Buy Boston Scientific Stock Despite Near-Term Risks?
Boston Scientific (BSX) cut its 2026 guidance, lowering organic sales growth to 5% to 6% from 6.5% to 8% and adjusted EPS to $3.28 to $3.32 from $3.34 to $3.41. Management expects Q3 organic growth of 3% to 5% and only 0% to 25 bps operating-margin expansion. WATCHMAN demand weakened and U.S. electrophysiology lost share.
7 min read
Boston Scientific’s Q2 Earnings Call: Our Top 5 Analyst Questions
Boston Scientific (BSX) reported Q2 revenue of $5.44B vs $5.36B estimates and adjusted EPS of $0.86 vs $0.83. Management said Interventional Cardiology, Endoscopy and Neuromodulation grew, while Electrophysiology and WATCHMAN slowed. CEO Michael Mahoney cited U.S. WATCHMAN market changes and competition, leading to lower Q3 revenue guidance and reduced full-year adjusted EPS midpoint to $3.30.
6 min read
FDA announces highest recall for certain ventilators, introducer kits
The FDA announced multiple Class I recalls and alerts involving medical devices and related products. Items include certain ventilators and introducer kits, reprocessed electrophysiology and ultrasound catheters by Medline Industries, heart pump controllers by Abiomed, Boston Scientific ACCOLADE pacemakers, and dialysis catheter kits involving Arrow International and Merit Medical. These actions may affect supply and compliance for healthcare providers and investors.
4 min readLUDWIG EDWARD J purchased $227K of BSX
LUDWIG EDWARD J purchased 5,000 shares of BOSTON SCIENTIFIC CORP (BSX) at $45.48 ($0.23M total) on 2026-07-31.
1 min read
Boston Scientific Announces Global Restructuring: What It Means for Operations in Costa Rica ⋆ The Costa Rica News
Boston Scientific said its board approved a global restructuring plan on July 21, citing cost cuts and supply-chain optimization. The phased rollout runs from 2026 through late 2029, with estimated pre-tax costs of $700 million to $800 million and cash outflows of $600 million to $700 million. It projects about $500 million in annual savings once complete, while not specifying impacts in Costa Rica.
4 min readBSX Q2 Deep Dive: WATCHMAN and Electrophysiology Challenges Temper Growth Outlook
Boston Scientific reported Q2 revenue of $5.44B (vs $5.36B est.) and adjusted EPS of $0.86 (vs $0.83). Q3 2026 revenue guidance midpoint is $5.27B (below $5.39B est.), and full-year adjusted EPS guidance midpoint was cut to $3.30. WATCHMAN growth slowed and U.S. electrophysiology faced PFA competition; restructuring targets $500M run-rate savings by 2029.
6 min readWeekly Buzz: Cipla, Viatris Win FDA Nod; Boston Scientific Cuts Jobs; argenx Snaps Up Forte Biosciences; Johnson & Johnson, GSK Strike Deals
A weekly healthcare roundup cites multiple corporate events: Cipla and Viatris received U.S. FDA approvals, Boston Scientific announced job cuts, argenx agreed to acquire Forte Biosciences, and Johnson & Johnson and GSK reached deal terms. It highlights regulatory, M&A, and restructuring developments that can affect sector sentiment and individual stock performance.
4 min read